We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CryoLife Inc | NYSE:CRY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.88 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of ear
liest event reported):
June 19, 2018
(Exact name of registrant as specified in its charter)
_________________________
Florida |
1-13165 |
59-2417093 |
(State or Other Jurisdiction
|
(Commission File Number) |
(IRS Employer Identification No.) |
1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (770) 419-3355
_____________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On June 1 9 , 201 8 , the Board of Directors (the “Board”) of CryoLife, Inc. a Florida corporation (NYSE: CRY) (the “Company”) increased the size of the Company’s Board to nine members and elected Marna P. Borgstrom as a director of the Company. M s . B orgstrom will be included as one of the Company’s directors who will stand for reelection by the Company’s shareholders at the Company’s Annual Meeting to be held in May 201 9 . On June 19 , 201 8 , the Company issued a press release regarding M s . B orgstrom ’s appointment, a copy of which is attached hereto.
The Board has affirmatively determined th at M s . B orgstrom qualifies as an independent director under the categorical standards of the corporate governance rules of New York Stock Exchange as defined under applicable law.
There are no arrangements or understandings between M s . B orgstrom and any person pursuant to which M s . B orgstrom was selected as a director, and there are no actual or proposed transactions between M s . B orgstrom or any of her related persons and the Company that would require disclosure under Item 404(a) of Regulation S-K (17 CFR 22 9.404(a)) in connection with her appointment as a director of the Company.
As of the date of her appointment, Ms . B orgstrom is entitled to receive compensation and participate in the plans of the Company applicable to all of the Company’s directors, as more particularly described on page 1 9 of the Comp any’s proxy statement filed April 3 , 201 8 , under th e sub-heading “Elements of Non-Employee Director Compensation ” . In accordance with such plans, M s . B orgstrom will be granted, as soon as practicable after any applicable trading blackout has been lifted, a restricted stock award value d at $ 114 , 583 on the grant date , such award to vest one year front grant . I n addition , commencing on July 1, 201 8 , M s . B orgstrom will receive monthly cash compensation for her service on the Board ($3, 750 /month) and for h er ser vice on the Compliance Committee ($ 416.66 / month ) until such time as the Company’s Board determine s to modify the cash component for director compensation or committee membership or M s . B orgstrom ceases to be a director or to serve on the C ompliance Committee . Each of the foregoing awards was made in respect of, and prorated to, M s . B orgstrom ’s service from the date of her appointment until the anticipated date of the Company’s next Annual Meeting.
Except as set forth above, there is no other material Company plan, contract or arrangement in which M s . Borgstrom will pa rticipate in connection with her appointment.
Section 9 Financial Statements and Exhibits.
Item 9.01(d) Exhibits
(a) Financial Statements
Not applicable
(b) Pro Forma Financial Information.
Not applicable.
(c) Shell Company Transactions.
Not applicable.
(d) Exhibits.
|
|
Exhibit Number |
Description |
99.1 * |
Press release dated June 19, 2018 |
*This exhibit is furnished, not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CRYOLIFE, INC. |
|
|
|
|
|
|
|
Date: June 20 , 2018 |
By: |
/s/ D. Ashley Lee |
|
Name: |
D. Ashley Lee |
|
Title: |
Executive Vice President, Chief Operating Officer and Chief Financial Officer |
1 Year CryoLife Chart |
1 Month CryoLife Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions